Saturday , November 18 2017
Home / Therapies / Sulfonylurea (page 9)

Sulfonylurea

ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #17: Insulin, Part 2 of 3

T1-diabetes-sourcebook

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor PEDIATRICS – Jane Lee Chiang, MD, and Georgeanna J. Klingensmith, MD ADULTS – Irl B. Hirsch, MD 1. Basal insulin accounts for ~50% of total daily dose: i. LAA (insulin glargine, detemir, degludec) or NPH if LAA …

Read More »

Avandia, Not Coumadin — Coumadin, Not Avandia

DCMS166DDAimage

From our partners at ISMP (Institute for Safe Medication Practices) – Last week the US Food and Drug Administration (FDA) notified health professionals about their determination that recent data for rosiglitazone-containing drugs, such as Avandia, combination products (Avandaryl [rosiglitazone and glimepiride] and Avandamet [rosiglitazone and metformin]), and generics, do not show an increased …

Read More »

Risk Factors for Hypoglycemia and Strategies for Avoidance

Minimizing hypoglycemia in type 2 diabetes patients…. Hypoglycemia is a common problem among patients taking combinations of insulin and sulfonylureas and may be a limiting factor in diabetes therapy management. Hypoglycemia is defined by the American Diabetes Association (ADA) as a plasma glucose of 79mg/dL. (3.9mmol/L) or less; however most people …

Read More »